CD8A and neoplasm: To assess the in vivo antitumor activity, we compared OT-I TRM-EHs (subcutaneous) and naïve OT-I CD8+ T cells (intravenous), as well as OT-I TRM-like cells (intravenous), in an MC38-OVA tumor prevention model (Fig. 4A).